Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
about
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).HIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cellsDiagnostic and prognostic biomarkers in melanoma.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourSerum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancerThe Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression AnalysisStudy protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study)Lactate Dehydrogenase Is an Important Prognostic Indicator for Hepatocellular Carcinoma after Partial Hepatectomy.Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.Serum lactate dehydrogenase and survival following cancer diagnosis.SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients.Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy.Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis.The evolution of S100B inhibitors for the treatment of malignant melanoma.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Biomarkers in melanoma.Metastatic pathways in patients with cutaneous melanoma.Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis.Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.Stage IV melanoma: completely resectable patients are scarce.Increased CCL17 serum levels are associated with improved survival in advanced melanoma.Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.[Surgical therapy for pulmonary metastases from malignant melanoma].
P2860
Q26770492-88599F07-891F-4BAE-B07A-B129C3A0CD3DQ31144246-5B3D84CB-7F46-45CD-A51A-B15BA1F5317FQ33648672-307FF426-CDAD-4D2F-BE8D-FB43F8A2D2BDQ33862470-3D18E2EE-1EA4-4E85-8C59-DE485251C81DQ34515007-6E84E949-6A3C-49E7-AF99-684D901863AEQ34702316-C61BFC3D-BED1-4B3D-911E-A53601254D47Q34794495-280F8849-AB94-459C-9EE9-74EAB4D8E341Q35060623-159A1536-FA7D-4BCD-BD0A-5331E9884E75Q35703129-0FF7BAAD-072E-402F-83B8-250295E6419EQ35740107-55CD12A1-169F-435A-A0B5-B277B82640C8Q35947544-FCAEC0F9-C331-4EE1-941A-C9ED4F1D1D2EQ36228928-AE2D6AA8-FD61-41A9-8F55-0C34E38ED61EQ36427506-CE5C183B-90F3-486E-877A-A0B3CC570632Q36545721-641C41A0-9A84-4ABE-AA01-0A0D84283A22Q36547923-6B506AC9-C2E3-431C-BA2F-AD2169DF8D8AQ36750612-8D69C6B0-94A7-4D10-822A-955B43240071Q36962895-B25F7016-123C-44E6-B0BC-666346AD5B6FQ37016576-43FFCDEA-6362-45BC-A869-2D499FAF4E40Q37702774-23DB3281-03BD-4159-801E-6FBEEC4D41C4Q37721680-2D730BCD-AA42-4EF6-90B0-B68A30388AD7Q37744341-47E74CC5-3DBC-4B6B-8FAA-62E7D8FB37E4Q38068971-3044E973-B7C0-4172-98F5-E8AF9E5D51D1Q38487988-51841801-AABD-4ABA-A7D8-81E314DE0339Q38620826-8CBC2AA3-969C-43BA-931D-17D14279E66EQ38911167-72677B7D-A0DD-4D1D-A39D-A88AF8579067Q39024316-F281E917-7E06-4DD9-888D-F92C2A02DFCAQ40051084-9ADD7044-BA63-42CF-8A97-FB95DBD6AA6CQ40286525-21ED7F0B-FE85-481C-8691-E42820BABD44Q40524925-380576DF-1953-43B2-8310-3B9457A741B3Q41056748-18D03F27-194F-4D79-A7C4-50C8415D3F62Q45349601-6DBE6A7B-E737-430E-AFAA-273DDF8D8F47Q46187804-428BC2E7-E6D5-4724-A61B-BB335D506410Q47812209-A8289CA8-4BF1-4AC5-9924-7F8CF3417339Q50873280-F7A1BF3A-B333-4A5A-9A8E-9066D8C0595BQ51023581-BB4BF718-A1FE-4DA3-BB3F-B6832F84C801Q51502194-B92E6A1E-1233-48E7-80C5-7F64E8A2F2F2Q52684209-57478CA2-D165-43C0-A4A2-D5EBAA5FAEDAQ52758918-7C98FCB2-7E6F-4FDD-B233-A046229D73ECQ53490356-C2ED70CF-AF6F-47C7-BF45-2C61C546E029Q53641146-615A244A-E9BC-4936-8B61-FD3416C34078
P2860
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Serum markers lactate dehydrog ...... ients with distant metastasis.
@ast
Serum markers lactate dehydrog ...... ients with distant metastasis.
@en
type
label
Serum markers lactate dehydrog ...... ients with distant metastasis.
@ast
Serum markers lactate dehydrog ...... ients with distant metastasis.
@en
prefLabel
Serum markers lactate dehydrog ...... ients with distant metastasis.
@ast
Serum markers lactate dehydrog ...... ients with distant metastasis.
@en
P2093
P2860
P356
P1476
Serum markers lactate dehydrog ...... ients with distant metastasis.
@en
P2093
A Pflugfelder
M Elsässer
T K Eigentler
P2860
P2888
P304
P356
10.1038/BJC.2012.306
P407
P577
2012-07-10T00:00:00Z
P6179
1051259551